GSK's Revolade recommended by UK's NICE for low blood platelet counts
The UK’s drugs watch dog the National Institute for Health and Care Excellence (NICE) has recommended that pharma major GlaxoSmithKline’s (LSE: GSK) Revolade (eltrombopag) be made available on the National Health Service for treatment of chronic immune thrombocytopenic purpura (ITP).
Final guidance from the NICE said the once-daily oral treatment, now available on the NHS, offers patients a clinically and cost-effective option to treat low blood platelet counts in adult chronic ITP (cITP).
Adrian Newland, clinical director for pathology, The Royal London Hospital quoted by GSK, said: “I was very pleased to see that NICE has recognized the clinical value and cost-effectiveness of eltrombopag in their guidance. With their recommendation on the use of eltrombopag within its licensed indication, we now have an important addition to the treatment options for patients with severe or refractory disease.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze